Charles River Laboratories International, Inc. $CRL Shares Sold by Swiss National Bank

Key Points

• Swiss National Bank has reduced its holdings in Charles River Laboratories by 32.1%, now owning approximately 99,100 shares valued at around $14.9 million.
• Multiple analysts have upgraded their ratings on CRL, with price targets ranging from $160.00 to $190.00, indicating a generally positive outlook for the company's stock.
• Charles River Laboratories reported earnings of $3.12 per share for the last quarter, exceeding expectations, with revenues totaling $1.03 billion.

Swiss National Bank cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 32.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 99,100 shares of the medical research company's stock after selling 46,800 shares during the quarter. Swiss National Bank owned about 0.20% of Charles River Laboratories International worth $14,917,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Two Sigma Securities LLC lifted its position in Charles River Laboratories International by 4.3% during the fourth quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock valued at $366,000 after purchasing an additional 81 shares during the period. Wahed Invest LLC lifted its position in Charles River Laboratories International by 6.5% during the fourth quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock valued at $244,000 after purchasing an additional 81 shares during the period. Teachers Retirement System of The State of Kentucky lifted its position in Charles River Laboratories International by 2.7% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company's stock valued at $589,000 after purchasing an additional 102 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Charles River Laboratories International by 2.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company's stock valued at $763,000 after purchasing an additional 105 shares during the period. Finally, Veracity Capital LLC lifted its position in Charles River Laboratories International by 3.4% during the first quarter. Veracity Capital LLC now owns 3,298 shares of the medical research company's stock valued at $496,000 after purchasing an additional 107 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CRL. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their price objective for the stock from $188.00 to $182.00 in a research report on Friday, May 23rd. Citigroup upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $150.00 to $200.00 in a research report on Wednesday, July 9th. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective for the company in a research report on Wednesday, May 14th. Wall Street Zen downgraded shares of Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research report on Sunday. Finally, Robert W. Baird upped their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Charles River Laboratories International has a consensus rating of "Hold" and an average target price of $175.69.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 400 shares of the stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $150.04, for a total transaction of $60,016.00. Following the sale, the executive vice president directly owned 24,916 shares in the company, valued at $3,738,396.64. This represents a 1.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Trading Up 0.4%

Shares of CRL stock traded up $0.59 during trading hours on Monday, hitting $157.27. The company had a trading volume of 128,163 shares, compared to its average volume of 1,277,642. The company's fifty day moving average is $156.87 and its 200 day moving average is $148.74. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $230.02. The stock has a market capitalization of $7.74 billion, a PE ratio of -118.07, a price-to-earnings-growth ratio of 5.00 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $983.76 million. During the same period in the prior year, the business posted $2.80 EPS. The business's revenue for the quarter was up .6% compared to the same quarter last year. Research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).